ArticleInternational braz j urol : official journal of the Brazilian Society of Urology
Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.
Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated withDiagnostics (Basel, Switzerland) · 2025Article
- Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer.Asia Oceania journal of nuclear medicine & biology · 2023Article
- Outcomes and Factors Associated with Completion of Radium-223 Therapy.Nuclear medicine and molecular imaging · 2022Article
- Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).Prostate cancer and prostatic diseases · 2022Article
- The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).European journal of nuclear medicine and molecular imaging · 2022Article
- Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.Future science OA · 2021Article
- Review of PalliativeJournal of nuclear medicine technology · 2021Observational
- Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.International journal of clinical oncology · 2021Article
- Single-center developing country analysis of radium-223 therapy in prostate cancer-preliminary results.American journal of nuclear medicine and molecular imaging · 2021Article
- Behavior of total alkaline phosphatase after radium-233 therapy in metastatic castration-resistant prostate cancer: a single-center, real-world retrospective study.Radiologia brasileiraArticle
- Editorial Comment: Overall survival prediction in metastatic castration resistant prostate cancer treated with radium-223.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- In these difficult times of COVID-19, urologic research cannot stop: COVID-19 pandemic and reconstructive urology highlighted in International Brazilian Journal of Urology.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRadium-223(223Ra) is indicated for patients (p) with metastatic castration resistant prostate cancer (mCRCP).
objectivesThe aim of this study was to evaluate the role of baseline clinical variables associated with overall survival (OS) and toxicity of 223Ra. Its purpose was to identify the factors that can predict a better response to treatment and provide information regarding the most appropriate time for the application of 223Ra. MATERIALS AND
methodsProspective study in 40p with mCRPC treated with 223Ra. End points were OS, progression-free survival and time to progression. The follow-up parameters were: doses received, hemoglobin (Hb), absolute neutrophil count (ANC), platelet count (PC), prostate specific antigen (PSA), alkaline phosphatase (ALP), Visual Analogue Scale for pain, Eastern Cooperative Oncology Group (ECOG) and WHO's Cancer Pain Ladder. The use of other treatments was also evaluated.
resultsMedian OS was 17.1 months(mo) (CI95%6.5-27.7); 26/40p received complete treatment of 223Ra, without reaching a median OS and 14p received incomplete treatment with a median OS 13.6mo(CI95%1.6-25.6). Median follow-up was 11.2mo (range:1.3-45.2). The univariate analysis showed that factors as VAS, ECOG, Hb and ALP values were independently associated with OS. First line treatment with 223Ra was started in 11/40p, while 19p had been heavily pre-treated and 13p received concomitant treatment.
conclusions223Ra therapy require an adequate selection of patients to obtain the greatest clinical benefit. Low basal Hb, hight basal ALP, bone marrow involvement and an altered ECOG were the main factors that decreased OS in our patients. 223Ra should be considered relatively early in the course of treatment. Available at. https://www.intbrazjurol.com.br/pdf/aop/2019-0343OA.pdf.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.